Clarity Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Clarity Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $7.13. The average 1-year stock price forecast is 292.84% higher than the current stock price, while the lowest is $5.20 (+186.50%) and the highest is $8.41 (+363.36%).

Price Target: $7.13 (+292.84%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.20	$7.13	$7.45	$8.41
Change	+186.50%	+292.84%	+310.47%	+363.36%

* Price targets were last updated on May 26, 2026.

Analyst Ratings

The average analyst rating for Clarity Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	4	4	4	4
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Madeleine Williams Canaccord Genuity	Canaccord Genuity	Buy Maintains $8.41	Buy	Maintains	$8.41	+363.36%	May 26, 2026
John Hester Bell Potter	Bell Potter	Buy Maintains $6.40 → $6.50	Buy	Maintains	$6.40 → $6.50	+258.13%	Apr 1, 2026

Financial Forecast

Revenue This Year

n/a

from 9.46M

-100.00%

from 9.46M

Revenue Next Year

933.33K

EPS This Year

-0.30

from -0.20

EPS Next Year

-0.33

from -0.30

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Jun 30, 2021	Jun 30, 2022	Jun 30, 2023	Jun 30, 2024	Jun 30, 2025	Jun 30, 2026
Revenue	3.20M	6.46M	9.80M	11.51M	9.46M	-
Revenue Growth	14.62%	102.07%	51.74%	17.41%	-17.76%	-100.00%
Gross Profit	3.20M	6.46M	9.80M	11.51M	9.46M	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Income	-10.31M	-17.05M	-26.36M	-44.21M	-69.09M	-115.71M
Net Income	-10.22M	-23.75M	-24.60M	-42.32M	-64.30M	-107.84M
EPS	-	-	-	-	-0.20	-0.30
Free Cash Flow	-3.90M	-7.23M	-19.59M	-29.16M	-33.70M	-96.25M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-100.0%
Avg	-100.0%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.25
Avg	-0.30
Low	-0.33

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-